MA38206A1 - Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées - Google Patents
Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associéesInfo
- Publication number
- MA38206A1 MA38206A1 MA38206A MA38206A MA38206A1 MA 38206 A1 MA38206 A1 MA 38206A1 MA 38206 A MA38206 A MA 38206A MA 38206 A MA38206 A MA 38206A MA 38206 A1 MA38206 A1 MA 38206A1
- Authority
- MA
- Morocco
- Prior art keywords
- hydrazones
- tuberculosis
- pyridyl
- related diseases
- treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- -1 Pyridyl hydrazones Chemical class 0.000 title abstract 2
- 201000008827 tuberculosis Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des pyridyl-hydrazones de formule (i), ou des sels, esters, solvates, isomères et promédicaments pharmaceutiquement acceptables de ceux-ci, ainsi que des compositions pharmaceutiques contenant ces composés, à utiliser pour le traitement prophylactique et/ou thérapeutique de la tuberculose et de maladies associées, par exemple, des maladies causées par des mycobactéries non tuberculeuses et/ou par
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT106652A PT106652A (pt) | 2012-11-20 | 2012-11-20 | Piridil hidrazonas para o tratamento de tuberculose e doenças relacionadas |
| PCT/PT2013/000068 WO2014081324A1 (fr) | 2012-11-20 | 2013-11-20 | Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38206A1 true MA38206A1 (fr) | 2017-12-29 |
| MA38206B1 MA38206B1 (fr) | 2019-03-29 |
Family
ID=49876952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38206A MA38206B1 (fr) | 2012-11-20 | 2013-11-20 | Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9593103B2 (fr) |
| EP (2) | EP3539543B1 (fr) |
| BR (1) | BR112015011606A2 (fr) |
| CY (2) | CY1121861T1 (fr) |
| DK (1) | DK2922541T3 (fr) |
| ES (2) | ES2899437T3 (fr) |
| HR (2) | HRP20211767T1 (fr) |
| HU (2) | HUE045502T2 (fr) |
| LT (2) | LT2922541T (fr) |
| MA (1) | MA38206B1 (fr) |
| PL (2) | PL2922541T3 (fr) |
| PT (3) | PT106652A (fr) |
| RS (2) | RS62579B1 (fr) |
| SI (2) | SI2922541T1 (fr) |
| WO (1) | WO2014081324A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115590857B (zh) * | 2021-07-08 | 2024-11-05 | 中国医学科学院药物研究所 | 化合物t0349在制备抗结核分枝杆菌药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3716131A1 (de) * | 1987-05-14 | 1988-12-01 | Forsch Borstel Inst Fuer Exper | Substituierte 2-acylpyridin-(alpha)-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel |
| US8865901B2 (en) * | 2009-10-02 | 2014-10-21 | Fred Hutchinson Cancer Research Center | Gain-of-function Bcl-2 inhibitors |
| EP2311457A1 (fr) * | 2009-10-19 | 2011-04-20 | Forschungszentrum Borstel | Compositions pharmaceutiques pour traiter les infections avec des mycobactéries résistantes aux médicaments |
-
2012
- 2012-11-20 PT PT106652A patent/PT106652A/pt unknown
-
2013
- 2013-11-20 RS RS20211433A patent/RS62579B1/sr unknown
- 2013-11-20 LT LTEP13811632.2T patent/LT2922541T/lt unknown
- 2013-11-20 HU HUE13811632A patent/HUE045502T2/hu unknown
- 2013-11-20 PL PL13811632T patent/PL2922541T3/pl unknown
- 2013-11-20 HR HRP20211767TT patent/HRP20211767T1/hr unknown
- 2013-11-20 LT LTEP19167996.8T patent/LT3539543T/lt unknown
- 2013-11-20 ES ES19167996T patent/ES2899437T3/es active Active
- 2013-11-20 ES ES13811632T patent/ES2741434T3/es active Active
- 2013-11-20 US US14/646,197 patent/US9593103B2/en active Active
- 2013-11-20 PT PT191679968T patent/PT3539543T/pt unknown
- 2013-11-20 SI SI201331543T patent/SI2922541T1/sl unknown
- 2013-11-20 HR HRP20191402 patent/HRP20191402T1/hr unknown
- 2013-11-20 WO PCT/PT2013/000068 patent/WO2014081324A1/fr not_active Ceased
- 2013-11-20 EP EP19167996.8A patent/EP3539543B1/fr active Active
- 2013-11-20 MA MA38206A patent/MA38206B1/fr unknown
- 2013-11-20 SI SI201331949T patent/SI3539543T1/sl unknown
- 2013-11-20 DK DK13811632.2T patent/DK2922541T3/da active
- 2013-11-20 HU HUE19167996A patent/HUE056531T2/hu unknown
- 2013-11-20 BR BR112015011606A patent/BR112015011606A2/pt not_active Application Discontinuation
- 2013-11-20 EP EP13811632.2A patent/EP2922541B1/fr active Active
- 2013-11-20 PL PL19167996T patent/PL3539543T3/pl unknown
- 2013-11-20 PT PT13811632T patent/PT2922541T/pt unknown
- 2013-11-20 RS RSP20191006 patent/RS59224B1/sr unknown
-
2019
- 2019-08-06 CY CY20191100833T patent/CY1121861T1/el unknown
-
2021
- 2021-11-26 CY CY20211101030T patent/CY1124836T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1121861T1 (el) | 2020-07-31 |
| LT2922541T (lt) | 2019-09-25 |
| DK2922541T3 (da) | 2019-08-12 |
| PL2922541T3 (pl) | 2019-10-31 |
| ES2899437T3 (es) | 2022-03-11 |
| EP3539543A1 (fr) | 2019-09-18 |
| RS59224B1 (sr) | 2019-10-31 |
| LT3539543T (lt) | 2021-12-27 |
| HRP20211767T1 (hr) | 2022-02-18 |
| MA38206B1 (fr) | 2019-03-29 |
| PT2922541T (pt) | 2019-08-26 |
| HUE045502T2 (hu) | 2019-12-30 |
| RS62579B1 (sr) | 2021-12-31 |
| PT106652A (pt) | 2014-05-20 |
| ES2741434T3 (es) | 2020-02-11 |
| US9593103B2 (en) | 2017-03-14 |
| SI2922541T1 (sl) | 2019-10-30 |
| HUE056531T2 (hu) | 2022-02-28 |
| EP3539543B1 (fr) | 2021-09-01 |
| BR112015011606A2 (pt) | 2017-07-11 |
| SI3539543T1 (sl) | 2022-01-31 |
| WO2014081324A1 (fr) | 2014-05-30 |
| US20150284374A1 (en) | 2015-10-08 |
| PT3539543T (pt) | 2021-11-22 |
| CY1124836T1 (el) | 2022-11-25 |
| PL3539543T3 (pl) | 2022-01-10 |
| EP2922541B1 (fr) | 2019-05-22 |
| HRP20191402T1 (hr) | 2019-11-15 |
| EP2922541A1 (fr) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA44674A (fr) | Inhibiteurs de bromodomaine | |
| MA38398B1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
| MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
| NZ708593A (en) | Novel pyrazole derivative | |
| CA2878796C (fr) | Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA38810A1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
| MA37886A1 (fr) | Nouvelles pyridinones bicycliques | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
| MA34746B1 (fr) | Dérivés de diphénylamine : utilisations, procédés de synthèse et compositions pharmaceutiques | |
| MA38206B1 (fr) | Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées |